Lv2
150 积分 2023-12-26 加入
Predictive factors of the clinical efficacy of ustekinumab in patients with refractory Crohn’s disease: tertiary centers experience in Japan
4个月前
已完结
Review article: loss of response to anti-TNF treatments in Crohn’s disease
4个月前
已完结
Crohn's disease
4个月前
已完结
Correspondence - Tranexamic acid for traumatic brain injury
4个月前
已关闭
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
4个月前
已完结
Resolving Loss of Response to Ustekinumab in Crohn’s Disease: POWER Through or Switch Treatment?
4个月前
已关闭
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
4个月前
已完结
Letter: ustekinumab for the treatment of post‐surgical and refractory Crohn's disease
4个月前
已完结
Predictive factors of the clinical efficacy of ustekinumab in patients with refractory Crohn’s disease: tertiary centers experience in Japan
4个月前
已完结
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST
4个月前
已完结
皖公网安备34019202002308
